The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Open accessAbstract
Reprogramming somatic cells to induced pluripotent stem (iPS) cells has been accomplished by expressing pluripotency factors and oncogenes, but the low frequency and tendency to induce malignant transformation compromise the clinical utility of this powerful approach. We address both issues by investigating the mechanisms limiting reprogramming efficiency in somatic cells. Here we show that reprogramming factors can activate the p53 (also known as Trp53 in mice, TP53 in humans) pathway. Reducing signalling to p53 by expressing a mutated version of one of its negative regulators, by deleting or knocking down p53 or its target gene, p21 (also known as Cdkn1a), or by antagonizing reprogramming-induced apoptosis in mouse fibroblasts increases reprogramming efficiency. Notably, decreasing p53 protein levels enabled fibroblasts to give rise to iPS cells capable of generating germline-transmitting chimaeric mice using only Oct4 (also known as Pou5f1) and Sox2. Furthermore, silencing of p53 significantly increased the reprogramming efficiency of human somatic cells. These results provide insights into reprogramming mechanisms and suggest new routes to more efficient reprogramming while minimizing the use of oncogenes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Knocking down p53 by shRNA increased the efficiency of cell reprogramming.”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [79]
In the citing paper
“Recently we, and others, showed that p53 activation contributed to the low frequency of generating induced pluripotent stem cells (iPS) during cell reprogramming [79,80].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Generation of germline-competent induced pluripotent stem cells
Okita, K., Ichisaka, T., & Yamanaka, S. (2007) · Nature · doi:10.1038/nature05934 · Cited by 4,438
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochiduki, Y., Takizawa, N., & Yamanaka, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1374 · Cited by 2,380
Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., Cha, K. Y., Lanza, R., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.05.005 · Cited by 1,814
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
The p53 Isoform Δ133p53β Promotes Cancer Stem Cell Potential
Arsic, N., Gadéa, G., Lagerqvist, E. L., Busson, M., Cahuzac, N., Brock, C., Hollande, F., Gire, V., Pannequin, J., & Roux, P. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.001 · Cited by 66
Chemical Strategies for Stem Cell Biology and Regenerative Medicine
Zhu, S., Wei, W., & Ding, S. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124715 · Cited by 66
Yang, C., Chang, K., & Rana, T. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.002 · Cited by 63
Wang, Y.-C., Stein, J. W., Lynch, C. L., Tran, H. T. T., Lee, C.-Y., Coleman, R., Hatch, A., Antontsev, V. G., Chy, H. S., O’Brien, C., et al. (2015) · Scientific Reports · doi:10.1038/srep13317 · Cited by 64
Self-citationEmerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
Olivos, D. J., & Mayo, L. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121982 · Cited by 67
Aarts, M., Georgilis, A., Beniazza, M., Beolchi, P., Banito, A., Carroll, T., Kulisic, M., Kaemena, D. F., Dharmalingam, G., Martin, N., et al. (2017) · Genes & Development · doi:10.1101/gad.297796.117 · Cited by 64
MicroRNAs in pluripotency, reprogramming and cell fate induction
Lüningschrör, P., Hauser, S., Kaltschmidt, B., & Kaltschmidt, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.03.025 · Cited by 64
Park, S. J., Yeo, H. C., Kang, N., Kim, H., Lin, J., Ha, H., Vendrell, M., Lee, J., Chandran, Y., Lee, D., et al. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.03.002 · Cited by 65
Gastric Cancer With Primitive Enterocyte Phenotype
Yamazawa, S., Ushiku, T., Shinozaki‐Ushiku, A., Hayashi, A., Iwasaki, A., Abé, H., Tagashira, A., Yamashita, H., Seto, Y., Aburatani, H., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000869 · Cited by 63
Turinetto, V., Orlando, L., & Giachino, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091952 · Cited by 71
Effect of Dedifferentiation on Time to Mutation Acquisition in Stem Cell-Driven Cancers
Jilkine, A., & Gutenkunst, R. N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003481 · Cited by 64
microRNA‐17‐92 cluster is a direct Nanog target and controls neural stem cell through Trp53inp1
Garg, N., Pò, A., Miele, E., Campese, A. F., Begalli, F., Silvano, M., Infante, P., Capalbo, C., Smaele, E. D., Canettieri, G., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.214 · Cited by 63
TP53 in Biology and Treatment of Osteosarcoma
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 66
Biomarkers of Cancer Stem Cells for Experimental Research and Clinical Application
Saito, S., Ku, C., Wuputra, K., Pan, J.-B., Lin, C., Lin, Y., Wu, D., & Yokoyama, K. K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050715 · Cited by 66
Cellular Senescence in Aging Lungs and Diseases
Aghali, A., Ngassie, M. L. K., Pabelick, C. M., & Prakash, Y. S. (2022) · Cells · doi:10.3390/cells11111781 · Cited by 67
A Cyclic AMP Analog, 8-Br-cAMP, Enhances the Induction of Pluripotency in Human Fibroblast Cells
Wang, Y., & Adjaye, J. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9209-3 · Cited by 62
Self-citationWalia, B., Satija, N. K., Tripathi, R. P., & Gangenahalli, G. U. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9279-x · Cited by 62
Ojo, D., Lin, X., Wong, N., Gu, Y. J., & Tang, D. (2015) · Cancers · doi:10.3390/cancers7040890 · Cited by 64
SOX17 in cellular reprogramming and cancer
Tan, D. S., Holzner, M., Weng, M., Srivastava, Y., & Jauch, R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.008 · Cited by 67
Tran, T.-O., Vo, T. H., Lam, L. H. T., & Le, N. Q. K. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.02.045 · Cited by 61
Nicotinamide Overcomes Pluripotency Deficits and Reprogramming Barriers
Son, M. J., Son, M., Seol, B., Kim, M., Yoo, C. H., Han, M., & Cho, Y. S. (2013) · Stem Cells · doi:10.1002/stem.1368 · Cited by 64
Telomere rejuvenation during nuclear reprogramming
Marión, R. M., & Blasco, M. A. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.01.005 · Cited by 62
Induced pluripotent stem cells: what lies beyond the paradigm shift
Cox, J. L., & Rizzino, A. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009267 · Cited by 62
The p53–PUMA axis suppresses iPSC generation
Li, Y., Feng, H., Gu, H., Lewis, D. W., Yuan, Y., Zhang, L., Yu, H. M., Zhang, P., Cheng, H., Miao, W., et al. (2013) · Nature Communications · doi:10.1038/ncomms3174 · Cited by 64
Li, D., Wang, L., Hou, J., Shen, Q., Chen, Q., Wang, X., Du, J., Cai, X., Shan, Y., Zhang, T., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.001 · Cited by 63
Jiang, Y., Liu, F., Zou, F., Zhang, Y., Wang, B., Zhang, Y., Lian, A., Han, X., Liu, Z., Liu, X., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1382-y · Cited by 60
Ishida, T., Nakao, S., Ueyama, T., Harada, Y., & Kawamura, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00117-8 · Cited by 60
Self-citationBiswal, B. K., Beyrouthy, M. J., Hever-Jardine, M. P., Armstrong, D., Tomlinson, C. R., Christensen, B. C., Marsit, C. J., & Spinella, M. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053003 · Cited by 63
Progress and Promise Towards Safe Induced Pluripotent Stem Cells for Therapy
Seifinejad, A., Tabebordbar, M., Baharvand, H., Boyer, L. A., & Salekdeh, G. H. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9121-x · Cited by 59
Deng, Y., Liu, Q., Luo, C., Chen, S., Li, X., Wang, C., Liu, Z., Lei, X., Zhang, H., Sun, H., et al. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0018 · Cited by 61
Human induced pluripotent stem cells—from mechanisms to clinical applications
Drews, K., Józefczuk, J., Prigione, A., & Adjaye, J. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0913-0 · Cited by 59
Solá, S., Xavier, J. M., dos Santos, D. M., Aranha, M. M., Morgado, A. L., Jepsen, K., & Rodrigues, C. M. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018421 · Cited by 61
Protein intrinsic disorder and induced pluripotent stem cells
Xue, B., Oldfield, C. J., Van, Y.-Y. J., Dunker, A. K., & Uversky, V. N. (2011) · Molecular BioSystems · doi:10.1039/c1mb05163f · Cited by 60
Martins, A. M., Vunjak‐Novakovic, G., & Reis, R. L. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9487-7 · Cited by 60
Gene-delivery systems for iPS cell generation
Shao, L., & Wu, W.-S. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903455989 · Cited by 63
Lü, Y., Qu, H., Qi, D., Xu, W., Liu, S., Jin, X., Song, P., Guo, Y., Jia, Y., Wang, X., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1120-x · Cited by 58
One billion years of p53/p63/p73 evolution
Белый, В. А., & Levine, A. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910634106 · Cited by 58
Song, J., Kang, S. M., Kim, E., Kim, C. H., Song, H.-T., & Lee, J. E. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.220 · Cited by 58
Three-dimensional growth of iPS cell-derived smooth muscle cells on nanofibrous scaffolds
Xie, C., Hu, J. Y., Ma, H., Zhang, J., Chang, L.-J., Chen, Y. E., & Ma, P. X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.049 · Cited by 58
Gerona‐Navarro, G., Yoel-Rodríguez, Mujtaba, S., Frasca, A., Patel, J. A., Zeng, L., Plotnikov, A. N., Osman, R., & Zhou, M. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107761h · Cited by 57
Ménendez, S., Camus, S., Herreria, A., Paramonov, I., Batlle‐Morera, L., Collado, M., Pekařík, V., Maceda, I., Edel, M. J., Consiglio, A., et al. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00754.x · Cited by 58
Self-citationLe, R., Kou, Z., Jiang, Y., Li, M., Huang, B. S., Liu, W., Li, H., Kou, X., He, W., Rudolph, K. L., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.005 · Cited by 58
de Jesus, B. B., Marinho, S. P., Barros, S. A., Sousa‐Franco, A., Alves‐Vale, C., Carvalho, T., & Carmo‐Fonseca, M. (2018) · Nature Communications · doi:10.1038/s41467-017-01921-6 · Cited by 59
Tied Up in Loops: Positive and Negative Autoregulation of p53Preprint
Lü, X. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000984 · Cited by 58
Multifaceted Regulation of Somatic Cell Reprogramming by mRNA Translational Control
Tahmasebi, S., Alain, T., Rajasekhar, V. K., Zhang, J.-P., Prager‐Khoutorsky, M., Khoutorsky, A., Dogan, Y., Gkogkas, C. G., Petroulakis, E., Sylvestre, A., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.02.005 · Cited by 54
Netrin-1 regulates somatic cell reprogramming and pluripotency maintenance
Ozmadenci, D., Féraud, O., Markossian, S., Kress, E., Ducarouge, B., Gibert, B., Ge, J., Durand, I., Gadot, N., Plateroti, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8398 · Cited by 70
Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine
Qiao, Y., Agboola, O. S., Hu, X., Wu, Y., & Lei, L. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10042-5 · Cited by 57
Zhang, M., Kumar, B., Piao, L., Xie, X., Schmitt, A. C., Arradaza, N., Cippola, M., Old, M. O., Agrawal, A., Ozer, E. K., et al. (2013) · Cancer · doi:10.1002/cncr.28538 · Cited by 56
Nishino, K., Toyoda, M., Yamazaki‐Inoue, M., Makino, H., Fukawatase, Y., Chikazawa, E., Takahashi, Y., Miyagawa, Y., Okita, H., Kiyokawa, N., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013017 · Cited by 55
Chistiakov, D. A. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-92 · Cited by 59
Regenerative medicine. Opportunities and challenges: a brief overview
Polak, J. M. (2010) · Journal of The Royal Society Interface · doi:10.1098/rsif.2010.0362.focus · Cited by 56
Pandian, G., Shinohara, K., Ohtsuki, A., Nakano, Y., Masafumi, M., Bando, T., Nagase, H., Yamada, Y., Watanabe, A., Terada, N., et al. (2011) · ChemBioChem · doi:10.1002/cbic.201100597 · Cited by 51
MYC and the Art of MicroRNA MaintenancePreprint
Psathas, J. N., & Thomas‐Tikhonenko, A. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014175 · Cited by 55
Energy Metabolism in Nuclear Reprogramming
Folmes, C. D. L., Nelson, T. J., & Terzic, A. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.87 · Cited by 57
Boué, S., Paramonov, I., Barrero, M. J., & Belmonte, J. C. I. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012664 · Cited by 55
Self-citationTurning terminally differentiated skeletal muscle cells into regenerative progenitors
Wang, H., Lööf, S., Borg, P., Nader, G. A., Blau, H. M., & Simon, A. (2015) · Nature Communications · doi:10.1038/ncomms8916 · Cited by 53
Wang, Y. V., Leblanc, M., Fox, N., Mao, J.-H., Tinkum, K. L., Krummel, K., Engle, D., Piwnica-Worms, D., Piwnica-Worms, H., Balmain, A., et al. (2011) · Genes & Development · doi:10.1101/gad.2024411 · Cited by 53
Self-citationLinking Pluripotency Reprogramming and Cancer
Iglesias, J. M., Gumuzio, J., & Martín, Á. G. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0225 · Cited by 53
p53 orchestrates between normal differentiation and cancer
Rivlin, N., Koifman, G., & Rotter, V. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.006 · Cited by 56
Folmes, C. D. L., Martinez‐Fernandez, A., Faustino, R. S., Yamada, S., Pérez-Terzic, C. M., Nelson, T. J., & Terzic, A. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9431-2 · Cited by 56
Pax3 Stimulates p53 Ubiquitination and Degradation Independent of Transcription
Wang, X. D., Morgan, S. C., & Loeken, M. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029379 · Cited by 53
Multifaceted role for p53 in pancreatic cancer suppression
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211937120 · Cited by 55
Reprogramming and Carcinogenesis—Parallels and Distinctions
Wasik, A. M., Grabarek, J., Pantovic, A., Cieślar‐Pobuda, A., Asgari, H. R., Bundgaard‐Nielsen, C., Rafat, M., Dixon, I., Ghavami, S., & Łoś, M. (2014) · International review of cytology · doi:10.1016/b978-0-12-800097-7.00005-1 · Cited by 54
Artyomov, M. N., Meissner, A., & Chakraborty, A. K. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000785 · Cited by 52
Fu, X., & Xu, Y. (2012) · Genome Medicine · doi:10.1186/gm354 · Cited by 55
Mechanistic insights into reprogramming to induced pluripotency
Ho, R., Chronis, C., & Plath, K. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22450 · Cited by 57
p53 Counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition
Brosh, R., Assia-Alroy, Y., Molchadsky, A., Bornstein, C., Dekel, E., Madar, S., Shetzer, Y., Rivlin, N., Goldfinger, N., Sarig, R., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.125 · Cited by 56
Switching cell fate, ncRNAs coming to play
Guan, D., Zhang, W., Zhang, W., Liu, G.-H., & Belmonte, J. C. I. (2013) · Cell Death and Disease · doi:10.1038/cddis.2012.196 · Cited by 52
Self-citationAulicino, F., Theka, I., Ombrato, L., Lluı́s, F., & Cosma, M. P. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.04.001 · Cited by 54
Zhou, R., Xu, A., Gingold, J. A., Strong, L. C., Zhao, R., & Lee, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.004 · Cited by 52
Raya, Á., Rodríguez-Pizà, I., Navarro, S., Richaud‐Patín, Y., Güenechea, G., Sánchez‐Danés, A., Consiglio, A., Bueren, J. A., & Belmonte, J. C. I. (2010) · Nature Protocols · doi:10.1038/nprot.2010.9 · Cited by 52
Self-citationJiao, J., Dang, Y., Yang, Y., Gao, R., Zhang, Y., Kou, Z., Sun, X., & Gao, S. (2013) · Stem Cells · doi:10.1002/stem.1318 · Cited by 51
Translating Induced Pluripotent Stem Cells from Bench to Bedside: Application to Retinal Diseases
Barnea-Cramer, A. O., & MacLaren, R. E. (2013) · Current Gene Therapy · doi:10.2174/1566523211313020008 · Cited by 50
He, J., Kang, L., Wu, T., Zhang, J., Wang, H., Gao, H., Zhang, Y., Huang, B., Liu, W., Kou, Z., et al. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0015 · Cited by 51
Ouyang, J., Yu, W., Liu, J., Zhang, N., Florens, L. A., Chen, J., Liu, H., Washburn, M. P., Pei, D., & Xie, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.658195 · Cited by 51
Zhai, Y., Chen, X. X., Yu, D., Li, T., Cui, J., Wang, G., Hu, J., & Li, W. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.06.003 · Cited by 56
Cell senescence as both a dynamic and a static phenotype
Young, A. R. J., Narita, M., & Narita, M. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_1 · Cited by 50
How induced pluripotent stem cells are redefining personalized medicine
Ferreira, L. M. R., & Mostajo-Radji, M. A. (2013) · Gene · doi:10.1016/j.gene.2013.02.037 · Cited by 52
Stimulation of Somatic Cell Reprogramming by ERas‐Akt‐FoxO1 Signaling Axis
Yu, Y. S., Liang, D., Tian, Q., Chen, X.-N., Jiang, B., Chou, B.-K., Hu, P., Cheng, L.-Z., Gao, P., Li, J., et al. (2014) · Stem Cells · doi:10.1002/stem.1447 · Cited by 49
Clinical Therapy Using iPSCs: Hopes and Challenges
Lu, X., & Zhao, T. (2013) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2013.09.002 · Cited by 52
A Stochastic Model of Epigenetic Dynamics in Somatic Cell Reprogramming
Flöttmann, M., Scharp, T., & Klipp, E. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00216 · Cited by 50
The Role of the p53 Protein in Stem-Cell Biology and Epigenetic RegulationPreprint
Levine, A. J., Puzio‐Kuter, A. M., Chan, C. S., & Hainaut, P. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026153 · Cited by 53
Concise Review: Harmonies Played by MicroRNAs in Cell Fate Reprogramming
Moradi, S., Sassan Asgari, B., & Baharvand, H. (2013) · Stem Cells · doi:10.1002/stem.1576 · Cited by 48
Popowski, M., Templeton, T. D., Lee, B. K., Rhee, C., Li, H., Miner, C. A., Dekker, J. D., Orlanski, S., Bergman, Y., Iyer, V. R., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.12.002 · Cited by 49
A Combined Epigenetic and Non-Genetic Approach for Reprogramming Human Somatic Cells
Han, J., Sachdev, P. S., & Sidhu, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012297 · Cited by 49
Kwon, D., Kim, J., Cha, B.-H., Park, K., Han, I., Park, K., Bae, H., Han, M., Kim, K., & Lee, S. (2016) · Cell Transplantation · doi:10.3727/096368915x689703 · Cited by 51
iPSCs: On the Road to Reprogramming Aging
Soria‐Valles, C., & López-Otı́n, C. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.010 · Cited by 49
Ray, A., Joshi, J. M., Sundaravadivelu, P. K., Raina, K., Lenka, N., Kaveeshwar, V., & Thummer, R. P. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10200-3 · Cited by 56
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 53
Gu, H., Huang, X., Xu, J., Song, L., Liu, S., Zhang, X., Yuan, W., & Li, Y. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0908-z · Cited by 47
Generation of induced pluripotent stem cells using site-specific integration with phage integrase
Ye, L., Chang, J. C., Lin, C., Qi, Z.-X., Yu, J.-W., & Kan, Y. (2010) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1012677107 · Cited by 51
Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells
Yamashita, A., Liu, S., Woltjen, K., Thomas, B., Meng, G., Hotta, A., Takahashi, K., Ellis, J., Yamanaka, S., & Rancourt, D. E. (2013) · Scientific Reports · doi:10.1038/srep01978 · Cited by 48
Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells
Liu, Y.-J., Cheng, H., Gao, S., Lu, X., He, F., Hu, L., Hou, D., Zou, Z., Li, Y., Zhang, H., et al. (2013) · Leukemia · doi:10.1038/leu.2013.304 · Cited by 50
Cells, Stem Cells, and Cancer Stem Cells
Aguilar-Gallardo, C., & Simón, C. (2013) · Seminars in Reproductive Medicine · doi:10.1055/s-0032-1331792 · Cited by 48
JMJD5 Regulates Cell Cycle and Pluripotency in Human Embryonic Stem Cells
Zhu, H., Hu, S., & Baker, J. C. (2014) · Stem Cells · doi:10.1002/stem.1724 · Cited by 49
Advanced Feeder-Free Generation of Induced Pluripotent Stem Cells Directly From Blood Cells
Trokovic, R., Weltner, J., Nishimura, K., Ohtaka, M., Nakanishi, M., Salomaa, V. V., Jalanko, A., Otonkoski, T., & Kyttälä, A. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0113 · Cited by 48
Evolution of induced pluripotent stem cell technology
Zhou, H., & Ding, S. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328339f2ee · Cited by 48
Reduced replication fork speed promotes pancreatic endocrine differentiation and controls graft size
Sui, L., Xin, Y., Du, Q., Georgieva, D., Diedenhofen, G., Haataja, L., Su, Q., Zuccaro, M. V., Kim, J., Fu, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141553 · Cited by 47
Self-citationVelasco, I., Salazar, P., Giorgetti, A., Ramos–Mejía, V., Castaño, J., Romero–Moya, D., & Menéndez, P. R. (2014) · Stem Cells · doi:10.1002/stem.1782 · Cited by 49
Kinoshita, T., Nagamatsu, G., Kosaka, T., Takubo, K., Hotta, A., Ellis, J., & Suda, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.013 · Cited by 46
Metadata
- Authors
- Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Wahl, Geoffrey M.
- Belmonte, Juan Carlos Izpisúa
- Venue
- Nature
- Published
- 2009-08
- Volume
- 460
- Issue
- 7259
- Pages
- 1140-1144
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2735889
- OpenAlex
- W2070672434
- Cited by
- 1,115
- References
- 40
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 30 · 2023: 34 · 2022: 31 · 2021: 36 · 2020: 29 · 2019: 41 · 2018: 55 · 2017: 60 · 2016: 65 · 2015: 77 · 2014: 96 · 2013: 111 · 2012: 136
- FWCI
- 57.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R33HL088293)
- National Cancer Institute (R01CA100845, R01CA061449)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- p53, somatic cell reprogramming, induced pluripotent stem cells, Oct4, SOX2, p21, Nutlin-3, reprogramming efficiency, malignant transformation, fibroblasts, oncogenes, apoptosis
- MeSH terms
- Animals, Cells, Cultured, Embryo, Mammalian, Female, Fibroblasts, Humans, Male, Mice, Inbred C57BL, Down-Regulation, Keratinocytes, Tumor Suppressor Protein p53, Pluripotent Stem Cells, Cyclin-Dependent Kinase Inhibitor p21, Mice, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
